Nec-1s

Alternative name

5 – ((7-Cl-1H-indol-3-yl) methyl) -3-methylimidazolidine-2,4-dione); 7-Cl-O-Nec-1

Peptide sequence: No

Appearance: Solid yellow

CAS #: 852391-15-2

Molecular formula: C₁₃H₁₂ClN₃O₂

Molecular weight: 277.71

Purity: ≥96% by TLC and LC-MS

Solubility: DMSO

SMILES

CN1C (= O) C (NC1 = O) CC2 = CNC3 = C2C = CC = C3Cl

InChi

InChI = 1S / C13H12ClN3O2 / c1-17-12 (18) 10 (16-13 (17) 19) 5-7-6-15-11-8 (7) 3-2-4-9 (11) 14 / h2-4,6,10,15H, 5H2,1H3, (H, 16,19)

InChi key

WIKGAEMMNQTUGL-UHFFFAOYSA-N

PubChem CID: 643953

Handling: Protect from light and moisture.

Storage conditions: -20 ° C

Shipping conditions: Gel Pack

USE: For research use only! It is not for use in humans.

Abstract

Necrostatin-1 (NEC-1) is widely used in disease models to examine the contribution of receptor-interacting protein kinase (RIPK) 1 in cell death and inflammation. We studied three Nec-1 analogues: Nec-1, the active inhibitor of RIPK1, inactive Nec-1 (Nec-1i), its inactive variant, and stable Nec-1 (Nec-1s), its most stable variant. We report that Nec-1 is identical to methyl-thiohydantoin-tryptophan, an inhibitor of the potent immunomodulatory enzyme indolamine 2,3-dioxygenase (IDO).

Both Nec-1 and Nec-1i inhibited human IDO, but Nec-1 did not, as predicted by molecular modelling. Therefore, Nec-1s is a more specific RIPK1 inhibitor that lacks the targeting effect of IDO. Next, although Nec-1i was approximately 100 times less effective than Nec-1 in inhibiting human RIPK1 kinase activity in vitro, it was only 10 times less potent than Nec-1 and Nec-1s in a necroptosis assay. in mice and became even equipotent at high concentrations.

Along the same lines, in vivo, high doses of Nec-1, Nec-1i and Nec-1s equally well-prevented tumour necrosis factor (TNF) -induced mortality, excluding the use of NEC-1i as an inactive control. Paradoxically, low doses of Nec-1 or Nec-1i, but not Nec-1s, even sensitized mice to TNF-induced mortality. Importantly, Nec-1s did not show this low dose toxicity, again emphasizing the preferred use of Nec-1 in vivo. Our findings have important implications for the interpretation of Nec-1-based data in experimental disease models.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post

BRCC3 Promotes Tumorigenesis of Bladder Cancer by Activating the NF-κB Signaling Pathway Through Targeting TRAF2

BRCC3 bevordert de tumorgenese van blaaskanker door de NF-KB-signaleringsroute te activeren door zich op TRAF2 te richtenBRCC3 bevordert de tumorgenese van blaaskanker door de NF-KB-signaleringsroute te activeren door zich op TRAF2 te richten

NF-KB-signalering is essentieel bij  kankers . Desalniettemin blijft de positie van BRCC3-geassocieerde NF-KB-signaleringsactivering in de meeste blaaskankers   gekarakteriseerd. Western blotting en  IHC  van  weefselmicroarray  zijn gebruikt om de onregelmatige expressie van BRCC3 in de meeste blaaskankers  te onderbouwen . Ontwikkelingscurve, kolonievorming, comfortabele agar-assay en xenograft-etalagepop zijn uitgevoerd

The inhibitory effect and mechanism of quetiapine on tumor progression in hepatocellular carcinoma in vivo

Het remmende effect en mechanisme van quetiapine op tumorprogressie bij hepatocellulair carcinoom in vivoHet remmende effect en mechanisme van quetiapine op tumorprogressie bij hepatocellulair carcinoom in vivo

Hepatocellulair carcinoom (HCC) is de eerste  tumor  van de lever en de vierde belangrijkste reden achter de  meeste aan kanker gerelateerde overlijdens. Nog niet zo lang geleden wees een aantal onderzoeken op het antitumorpotentieel  van antipsychotica. Quetiapine, een